Genenta Science S.p.A. SEC filings GNTA
Genenta Science S.p.A. has 119 filings in SEC EDGAR's recent list, going back to Mar 1, 2021. Its latest annual report, Form 20-F, was filed on Apr 1, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 2, 2026.
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 2, 2026 | Nov 2, 2026 |
| 6-K | Current report (foreign issuer) | Oct 22, 2026 | Oct 22, 2026 |
| 6-K | Current report (foreign issuer) | Oct 21, 2026 | Oct 21, 2026 |
| 6-K | Current report (foreign issuer) | Oct 13, 2026 | Oct 13, 2026 |
| 6-K | Current report (foreign issuer) | Oct 7, 2026 | Oct 7, 2026 |
| SCHEDULE 13D/A | Amended ownership over 5% (active) | Oct 2, 2026 | — |
| 6-K | Current report (foreign issuer) | Sep 11, 2026 | Sep 11, 2026 |
| 6-K | Current report (foreign issuer) | Sep 2, 2026 | Sep 1, 2026 |
| 6-K | Current report (foreign issuer) | Jul 31, 2026 | Jul 31, 2026 |
| 6-K | Current report (foreign issuer) | Jul 14, 2026 | Jul 14, 2026 |
| 6-K | Current report (foreign issuer) | Jul 1, 2026 | Jul 1, 2026 |
| 6-K | Current report (foreign issuer) | Jun 26, 2026 | Jun 26, 2026 |
| 6-K | Current report (foreign issuer) | Jun 24, 2026 | Jun 24, 2026 |
| 6-K | Current report (foreign issuer) | Jun 17, 2026 | Jun 17, 2026 |
| 6-K | Current report (foreign issuer) | Jun 16, 2026 | Jun 16, 2026 |
| 6-K | Current report (foreign issuer) | May 29, 2026 | May 29, 2026 |
| 6-K | Current report (foreign issuer) | May 19, 2026 | May 19, 2026 |
| SCHEDULE 13D | Ownership over 5% (active) | May 5, 2026 | — |
| 4 | Insider transaction | May 5, 2026 | Mar 30, 2026 |
| 6-K | Current report (foreign issuer) | Apr 28, 2026 | Apr 28, 2026 |
| 6-K | Current report (foreign issuer) | Apr 23, 2026 | Apr 23, 2026 |
| 6-K | Current report (foreign issuer) | Apr 14, 2026 | Apr 14, 2026 |
| 4 | Insider transaction | Apr 1, 2026 | Mar 30, 2026 |
| 4 | Insider transaction | Apr 1, 2026 | Mar 30, 2026 |
| 4 | Insider transaction | Apr 1, 2026 | Mar 30, 2026 |
| 4 | Insider transaction | Apr 1, 2026 | Mar 30, 2026 |
| 4 | Insider transaction | Apr 1, 2026 | Mar 30, 2026 |
| 20-F | Annual report (foreign issuer) | Apr 1, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Mar 27, 2026 | Mar 27, 2026 |
| 3 | Initial insider ownership | Mar 25, 2026 | Mar 18, 2026 |
| 6-K | Current report (foreign issuer) | Mar 24, 2026 | Mar 23, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 424B5 | Prospectus supplement | Jan 27, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Jan 27, 2026 | — |
| 6-K | Current report (foreign issuer) | Jan 27, 2026 | Jan 27, 2026 |
| 6-K | Current report (foreign issuer) | Jan 27, 2026 | Jan 27, 2026 |
| 6-K | Current report (foreign issuer) | Nov 4, 2025 | Oct 31, 2025 |
| 424B5 | Prospectus supplement | Oct 28, 2025 | — |
| 6-K | Current report (foreign issuer) | Oct 28, 2025 | Oct 28, 2025 |
| 6-K | Current report (foreign issuer) | Oct 27, 2025 | Oct 27, 2025 |
| 6-K | Current report (foreign issuer) | Oct 10, 2025 | Jun 30, 2025 |
| 6-K | Current report (foreign issuer) | Oct 3, 2025 | Oct 3, 2025 |
| 6-K | Current report (foreign issuer) | Sep 10, 2025 | Sep 10, 2025 |
| 6-K | Current report (foreign issuer) | Aug 1, 2025 | Aug 1, 2025 |
| 424B5 | Prospectus supplement | Mar 28, 2025 | — |
| 20-F | Annual report (foreign issuer) | Mar 28, 2025 | Dec 31, 2024 |
| 6-K | Current report (foreign issuer) | Mar 19, 2025 | Mar 19, 2025 |
| 6-K | Current report (foreign issuer) | Mar 19, 2025 | Mar 19, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 10, 2025 | — |
| 6-K | Current report (foreign issuer) | Dec 30, 2024 | Dec 30, 2024 |
| 6-K | Current report (foreign issuer) | Dec 20, 2024 | Dec 20, 2024 |
| 424B5 | Prospectus supplement | Dec 20, 2024 | — |
| 6-K | Current report (foreign issuer) | Dec 13, 2024 | Dec 13, 2024 |
| 6-K | Current report (foreign issuer) | Nov 14, 2024 | Nov 14, 2024 |
| 6-K | Current report (foreign issuer) | Oct 29, 2024 | Jun 30, 2024 |
| 6-K | Current report (foreign issuer) | May 3, 2024 | May 3, 2024 |
| 6-K | Current report (foreign issuer) | Apr 26, 2024 | Apr 26, 2024 |
| 424B5 | Prospectus supplement | Apr 26, 2024 | — |
| 6-K | Current report (foreign issuer) | Apr 8, 2024 | Apr 8, 2024 |
| 6-K | Current report (foreign issuer) | Apr 2, 2024 | Apr 2, 2024 |
| 20-F/A | Amended annual report (foreign issuer) | Apr 1, 2024 | Dec 31, 2023 |
| S-8 | Employee stock plan registration | Mar 29, 2024 | — |
| 20-F | Annual report (foreign issuer) | Mar 29, 2024 | Dec 31, 2023 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 12, 2024 | — |
| 6-K | Current report (foreign issuer) | Oct 20, 2023 | Jun 30, 2023 |
| 6-K | Current report (foreign issuer) | Jun 14, 2023 | Jun 14, 2023 |
| EFFECT | Filing | May 24, 2023 | — |
| CORRESP | Letter to the SEC | May 22, 2023 | — |
| UPLOAD | Letter from the SEC | May 22, 2023 | — |
| F-3 | Shelf registration (foreign issuer) | May 12, 2023 | — |
| 6-K | Current report (foreign issuer) | May 10, 2023 | May 10, 2023 |
| 6-K | Current report (foreign issuer) | May 1, 2023 | May 1, 2023 |
| 20-F | Annual report (foreign issuer) | Apr 21, 2023 | Dec 31, 2022 |
| 6-K | Current report (foreign issuer) | Mar 10, 2023 | Mar 10, 2023 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 10, 2023 | — |
| 6-K | Current report (foreign issuer) | Feb 1, 2023 | Jan 31, 2023 |
| 6-K | Current report (foreign issuer) | Dec 22, 2022 | Dec 22, 2022 |
| 6-K | Current report (foreign issuer) | Dec 15, 2022 | Dec 15, 2022 |
| 6-K | Current report (foreign issuer) | Oct 25, 2022 | Oct 25, 2022 |
| 6-K | Current report (foreign issuer) | Oct 25, 2022 | Jun 30, 2022 |
| 6-K | Current report (foreign issuer) | Oct 3, 2022 | Sep 30, 2022 |
| 6-K | Current report (foreign issuer) | Jun 14, 2022 | Jun 14, 2022 |
| 6-K | Current report (foreign issuer) | May 11, 2022 | May 11, 2022 |
| 20-F | Annual report (foreign issuer) | May 2, 2022 | Dec 31, 2021 |
| SC 13G | Ownership over 5% (passive) | Feb 25, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Feb 18, 2022 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2022 | — |
| SEC STAFF LETTER | Filing | Dec 16, 2021 | — |
| 424B1 | Filing | Dec 15, 2021 | — |
| 424B1 | Filing | Dec 15, 2021 | — |
| EFFECT | Filing | Dec 14, 2021 | — |
| F-1MEF | Filing | Dec 14, 2021 | — |
| CERT | Filing | Dec 14, 2021 | — |
| CORRESP | Letter to the SEC | Dec 10, 2021 | — |
| CORRESP | Letter to the SEC | Dec 10, 2021 | — |
| F-1/A | Filing | Dec 7, 2021 | — |
| CORRESP | Letter to the SEC | Dec 3, 2021 | — |
| 8-A12B | Filing | Dec 1, 2021 | — |
| CORRESP | Letter to the SEC | Nov 24, 2021 | — |
| F-1/A | Filing | Nov 24, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 12, 2021 | — |
| F-1 | Registration statement (foreign issuer) | Nov 9, 2021 | — |
| DRSLTR | Filing | Oct 29, 2021 | — |
| DRS/A | Filing | Oct 29, 2021 | — |
| SEC STAFF LETTER | Filing | Oct 21, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 21, 2021 | — |
| DRS/A | Filing | Oct 4, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 3, 2021 | — |
| DRS/A | Filing | May 19, 2021 | — |
| DRSLTR | Filing | May 19, 2021 | — |
| UPLOAD | Letter from the SEC | May 7, 2021 | — |
| DRSLTR | Filing | Apr 22, 2021 | — |
| DRS/A | Filing | Apr 22, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 29, 2021 | — |
| DRS | Filing | Mar 1, 2021 | — |
Showing 119 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- GNTA (Nasdaq)
- Incorporated in
- Italy
- Headquarters
- Milan, Italy
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1838716
- Former names
- Genenta Science S.r.l. (until May 19, 2021)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.